RE
0
Active Trials
0
Total Trials
0
Organizations
0
Events
Réunion
Medical Only (Private)
Reimbursed Care Access
Réunion, as an overseas department of France, is subject to French national drug law and health regulation. Medical access is available in restricted form for esketamine (SPRAVATO) under the French reimbursement/coverage framework and for ketamine as an established anesthetic and as off‑label psychiatric use in hospital settings; all classic psychedelic compounds (psilocybin, MDMA for non‑trial clinical use, DMT, 5‑MeO‑DMT, ibogaine, mescaline, ayahuasca and 2C‑X series) are controlled under French ‘stupéfiants’ law and have no routine reimbursed medical pathway outside authorised clinical research.
No clinical trials found for this country yet.